

Index

A

Aberrant T-cell antigen, 71
Acute leukemia, 79
Acute lymphoblastic leukemia, 24, 60, 84, 148, 165
Acute megakaryoblastic leukemia, 29
Acute monoblastic leukemia, 28
Acute myeloid leukemia, 24, 86, 101
ALK-positive histiocytosis, 10
Antigens, 185

B

B-cell clonality, 67
B-cell lymphoid proliferations, 4
B-cell neoplasm, 34
BCR::ABL1 Fusion – t(9;22), 176
BCR::ABL1 Fusion-like (Ph-like), 176
Biomarkers, 165
Blast population, 59
Blasts, 104
Bone marrow smear, 28, 36, 104
BRAF inhibitors, 43
BRAF^{V600E} mutation, 34

C

CD20, 185
CD45, 185
CDKN2A deletions, 184
Cell of origin, 132
Central nervous system, 26
Chemotherapy, 107

CHIC2 deletion, 134
Childhood ALL, 159
Chromosome 21, 180
Chromosome abnormalities, 105
Chronic eosinophilic leukemia, 140
Clinical characteristics, 24
Clinical classification, 167
Clinical features, 106
Clinical presentation, 35
Clonality assessment, 71
Consolidation therapy, 149
CPX-351 combinations, 117
CRLF2 deregulation rearrangements, 181
Cytogenetic abnormality, 66
Cytogenetics, 133
Cytology, 26, 30

D

Data acquisition, 58
Diagnosis, 53, 106
Diagnostic criteria, 106
Diagnostic evaluation, 138
Dic(9;20), 180
Differential diagnosis, 137
Digital PCR, 88
DNA ploidy, 66
Down syndrome, 24
DUX4 rearrangement, 182
Dyserythropoiesis, 103
Dysgranulopoiesis, 103
Dysmegakaryopoiesis, 103
Dysplasia, 103

E

Early relapse, 93
Eosinophilia, 137
Epidemiology, 34, 103
Etiopathogenesis of infant leukemias, 27
ETV6::RUNX1 Fusion – t(12;21), 174
ETV6::RUNX1 Fusion-like, 175

F

FGFR1 rearrangement, 139
First-line treatment, 39
Flow cytometry, 53
Fluorescence signals, 57
Fusion genes, 88

G

Gene alterations, 181
Genetic abnormalities, 10
Genetic biomarkers, 167
Genetic mutations, 106
Genetic variants, 151
Genetics, 133
Glucocorticoids, 152
GST genes, 154

H

Hairy cell leukemia, 33
Hematologic malignancies, 80
Hematolymphoid tumors, 1
Hematopoietic stem cell transplant,
107, 118
High hyperdiploidy, 168
HOX gene dysregulation, 30
Hyperdiploidy, 168
Hypereosinophilic syndrome, 138

Hypodiploidy, 174
Hypomethylating agent, 117

I

Ibrutinib, 45
IGH rearrangement, 182
IGH::IL3 Fusion – t(5;14), 180
IKZF1 alterations, 183
Immunophenotypic biomarkers, 184
Immunotherapy, 185
Incidence, 24
Induction chemotherapy, 149
Infant leukemia, 23
Intensification therapy, 150
Intensive chemotherapy, 115
Intrachromosomal amplification, 180

J

JAK inhibitors, 120
JAK/STAT alterations, 176
JAK2 rearrangements, 10, 140
Juvenile xanthogranuloma, 10

K

Karyotype, 133
KMT2A rearrangements, 27, 178

L

L-asparaginase, 152
Leukemia cutis, 25
Leukemias, 53
Light scatter, 56
Lineage-based classification, 2
Liver, 25
Low hyperdiploidy, 168

Low hypodiploid, 174
Lymphocytic variant, 141
Lymphoid neoplasms, 129
Lymphomas, 4

M

Maintenance therapy, 150
Mast cell, 132
Mature B-cell leukemias, 67
Mature B-cell neoplasms, 11
Measurable residual disease, 79
MEF2D rearrangement, 182
Mesenchymal dendritic cells, 6
Methotrexate, 153
Microscopy, 131
Molecular biomarkers, 167
Moxetumomab pasudotox, 42
Multiparameter flow cytometry, 82
Myelodysplasia related changes, 101
Myelodysplastic syndrome, 103
Myeloid neoplasms, 129
Myeloid precursor lesions, 10
Myeloid proliferations, 4

N

Near-haploid, 174
New drug testing, 94
Next-generation sequencing, 89
NK-cell lymphoid proliferations, 5
Non-intensive chemotherapy, 115
Noonan syndrome, 24
NUTM1 rearrangement, 182

O

Outcome, 166
Overall survival, 168

P

Pathobiology, 135
Pathogenesis, 34, 111, 113
PAX5 alterations, 183
PDGFRA receptor, 135
PDGFRA rearrangement, 129
Pediatric acute lymphoblastic
 leukemia, 24
Peripheral smear, 131
Pharmacogenetic testing, 159
Pharmacogenetic variants, 154
Pharmacogenetics, 151
Pharmacogenomics, 147
Plasma cell leukemia, 70
Plasmacytoid dendritic cell neoplasms, 10
Platelet derived growth factor receptor
 alpha, 129
Polymerase chain reaction, 87
Precursor B-cell, 165
Prognosis, 66, 108, 135
Prognostic prediction, 91

Q

Quality of life, 160

R

Relapse patterns, 80
Response to chemotherapy, 187
Risk stratification, 166
Rosai-Dorfman disease, 10

S

Secondary acute myeloid leukemia, 111
Surrogate endpoint, 94
Systemic mastocytosis, 142

T

T-cell proliferations, 5
TCF3 rearrangement, 179
Therapeutic implications, 92
Therapeutic response, 80
Therapy-related AML, 114
Thiopurines, 153
Toxicity, 150
Transient neonatal myelopoiesis, 30
Treatment, 107, 111, 135
Tyrosine kinase activity, 135

U

U2AF1, 112
Unbalanced abnormalities, 105

V

Valine, 34
Vemurafenib, 44

Venetoclax, 119

Vincristine, 152

W

WHO classification of hematolymphoid
tumors, 3

WHO classification

5th edition, 1, 14

World Health Organization, 1

X

X-linked gene mutations, 10

Y

Young adults, 177

Z

ZNF384 rearrangement, 8, 182

ZRSR2, 18, 112

DOI: <https://doi.org/10.36255/exon-publications-leukemia.index>